Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The effect of Acclydine on fatigue and functional status in patients with chronic fatigue syndrome
ISRCTN ISRCTN77271661
ClinicalTrials.gov identifier
Public title The effect of Acclydine on fatigue and functional status in patients with chronic fatigue syndrome
Scientific title
Acronym N/A
Serial number at source NTR167
Study hypothesis Acclydine is a plant sourced alkaloid which has effects on protein structure and metabolism. In particular it leads to the activation of the pituitary to increase release of growth hormone. The GH axis has been shown to be disturbed in chronic fatigue syndrome (CFS), so this alkaloid could be of benefit in CFS.
Ethics approval Received from local medical ethics committees
Study design Randomised double blind placebo-controlled parallel group trial
Countries of recruitment Netherlands
Disease/condition/study domain Chronic fatigue syndrome
Participants - inclusion criteria 1. Centre of Diseases Control (CDC)-diagnosed CFS-patients
2. Male and female patients aged 18 - 65 years
3. Elevated IGF-BP3/IGF-1 ratio
4. High-fatigue severity level
5. Substantial functional impairment
6. Written informed consent
Participants - exclusion criteria 1. Pregnancy
2. Lactating women
3. Participation in CVS treatment programs
4. Recent participation in other CVS treatment research
5. Psychiatric co-morbidity
Anticipated start date 22/10/2002
Anticipated end date 01/10/2005
Status of trial Completed
Patient information material
Target number of participants 60
Interventions 14 weeks acclydine combined with amino-acids.
Primary outcome measure(s) 1. Fatigue-severity measured with CIS-fatigue
2. Functional impairment measured with Sickness Impact Profile
3. CDC-symptoms
Secondary outcome measure(s) 1. Activity level measured with actometer
2. IGF-BP3-IGF-1 ratio
Sources of funding Optipharma BV (Netherlands)
Trial website
Publications 2007 results in http://www.ncbi.nlm.nih.gov/pubmed/17525791
Contact name Dr  J.W.M.  van der Meer
  Address University Medical Center St. Radboud
Department Internal Medicine
Expert Center Chronic Fatigue
P.O. Box 9101
  City/town Nijmegen
  Zip/Postcode 6500 HB
  Country Netherlands
  Tel +31 (0)24 3618819
  Email j.vandermeer@aig.umcn.nl
Sponsor University Medical Centre Nijmegen (Netherlands)
  Address P.O. Box 9101
  City/town Nijmegen
  Zip/Postcode 6500 HB
  Country Netherlands
  Tel +31 (0)24 361 1111
  Email info@ozi.umcn.nl
  Sponsor website: http://www.umcn.nl/homepage
Date applied 20/12/2005
Last edited 13/05/2009
Date ISRCTN assigned 20/12/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central